{"id":389908,"date":"2021-12-30T00:00:00","date_gmt":"2021-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2021-biopharma-psoriasis-disease-landscape-and-forecast-g7-2021\/"},"modified":"2026-03-31T10:41:19","modified_gmt":"2026-03-31T10:41:19","slug":"dlsfim0005-2021-biopharma-psoriasis-disease-landscape-and-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0005-2021-biopharma-psoriasis-disease-landscape-and-forecast-g7-2021\/","title":{"rendered":"Psoriasis | Disease Landscape and Forecast | G7 | 2021"},"content":{"rendered":"<p>The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12\/23 inhibitor ustekinumab (Janssen\u2019s Stelara) has been challenged by novel, highly effective IL-17 and IL-23 inhibitors. In particular, the uptake of risankizumab (AbbVie\u2019s Skyrizi)\u2014the latest IL-23 inhibitor to be approved for psoriasis\u2014has been phenomenal, raising an alarm for other approved biologics. The recent and expected approvals of bimekizumab, an IL-17 inhibitor; deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor; and the nonsteroidal topical agents roflumilast and tapinarof will further increase the number of psoriasis treatments and make the market even more competitive.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq \/ Lumicef) and the emerging IL-17 A\/F dual inhibitor bimekizumab, and where are\/will these agents be positioned in the psoriasis treatment algorithm?<\/li>\n<li>What will be the impact of the IL-23 inhibitors (Tremfya, Ilumya, and Skyrizi), and how will they fare in this competitive market?<\/li>\n<li>How will the oral TYK2 inhibitor deucravacitinib affect apremilast\u2019s (Amgen\u2019s Otezla\u2019s) patient share, and how will the two agents compare on efficacy and safety attributes?<\/li>\n<li>What will be the future of the novel topical therapies roflumilast, a PDE-4 inhibitor, and tapinarof, a TAMA?<\/li>\n<\/ul>\n<p><strong>Geographies:<\/strong> United States, France, Germany, Italy, Spain, United Kingdom, and Japan.<\/p>\n<p><strong>Primary research:<\/strong> 31 country-specific interviews with thought leaders. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology:<\/strong> Total diagnosed prevalence of psoriasis by country, segmented by mild and moderate to severe subpopulations.<\/p>\n<p><strong>Emerging therapies:<\/strong> Phase III\/PR: 6 drugs; Phase II: 9 drugs; coverage of select preclinical and Phase I products.<\/p>\n<p><strong>Forecast:<\/strong><strong> <\/strong> 10-year, annualized, drug-level sales and patient share of key psoriasis therapies through 2030, segmented by brands\/generics and epidemiological subpopulations.<\/p>\n","protected":false},"template":"","class_list":["post-389908","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389908","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389908\/revisions"}],"predecessor-version":[{"id":393033,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389908\/revisions\/393033"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389908"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}